Medscape (9/8, Brooks, Subscription Publication) reports, “Clozapine or antipsychotic polytherapy appear to be the best approach in reducing the risk for a substance use disorder (SUD) in adults with schizophrenia and for preventing relapse in patients with both diagnoses,” investigators concluded after analyzing “data on more than 45,000 patients with schizophrenia from Finnish and Swedish national registries, with follow-up lasting 22 years in Finland and 11 years in Sweden.” The findings were published online Aug. 25 in the British Journal of Psychiatry.
Related Links:
— Medscape (requires login and subscription)